|Bid||266.82 x 800|
|Ask||266.92 x 800|
|Day's Range||262.61 - 267.50|
|52 Week Range||229.40 - 277.29|
|Beta (5Y Monthly)||0.61|
|PE Ratio (TTM)||40.58|
|Earnings Date||Nov 02, 2022 - Nov 07, 2022|
|Forward Dividend & Yield||3.48 (1.32%)|
|Ex-Dividend Date||Sep 08, 2022|
|1y Target Est||274.55|
Subscribe to Yahoo Finance Plus to view Fair Value for BDX
The main point of investing for the long term is to make money. Furthermore, you'd generally like to see the share...
BD's (BDX) latest partnership is expected to provide life-changing treatments for cancer and other diseases, thereby improving patient care.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an innovator of rapid in-vitro diagnostics in microbiology, today announced a worldwide commercial collaboration agreement where BD will offer Accelerate's rapid testing solution for antibiotic resistance and susceptibility offering results in hours, versus one to two days with some traditional laboratory methods.